跳至主要内容
临床试验/NCT05706259
NCT05706259已完成不适用

A Comparative Vitamin D Bioavailability Study Following Supplementation of an Orodispersible, Chewable Tablet and Soft Gelatin Capsule Vitamin D3 Supplementation in Vitamin D Deficient Healthy Adults

Liaquat University of Medical & Health Sciences2 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
2
主要终点
Change in serum level of 25 (OH) D

研究概览

简要总结

This is an open-labelled, randomized controlled clinical trial aimed to compare the pharmacokinetics of an orodispersible vs a soft gelatin vitamin supplementation in vitamin D deficient healthy adults.

详细描述

Vitamin D is a fat-soluble vitamin used by the body for normal bone development and maintenance by increasing the absorption of calcium, magnesium, and phosphate. Vitamin D also plays a role in the nervous system, musculoskeletal system and immune system. Vitamin D deficiency has been linked with diverse health conditions including diabetes, cardiovascular diseases, breast, colorectal and prostate cancer, dementia, depression, erectile dysfunction, osteoporosis, and bone disorders. Vitamin D deficiency is a global healthcare challenge. To overcome vitamin D deficiency, a daily vitamin D supplementation of 200-1000 IU or a high dosage from 25000 to 200000 IU for 4-6 weeks, is normally recommended.

Vitamin D supplements are available over the counter in different delivery vehicles (formulations) to reach the circulatory system. In the present study the investigators aim to evaluate the pharmacokinetics of an orodispersible vitamin D supplement vs a conventional oral soft gelatin capsule, in vitamin D deficient healthy adults to assess how different vitamin D supplement formulations can efficiently overcome the vitamin D deficiency.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and female adults aged 18 - 60 years
  • Vitamin D deficiency as shown by serum levels of 25 (OH) D3 levels of < 20 ng/mL
  • Able to provide informed written consent

排除标准

  • Clinically significant abnormal laboratory parameters (such as complete blood count, CRP, d-dimer, liver enzymes, creatinine) indicative of physical illness, especially hypercalcemia and hypercalciuria
  • History of hypersensitivity to vitamin D3 supplements
  • History of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine, or neurological diseases
  • Prior use of medications in general containing calcium, magnesium, or vitamin D3, four weeks before the start of the study
  • Participation in the evaluation of any investigational product or blood donations in the last three months before this study
  • Any other significant disease or disorder that, in the opinion of the Physician, may either put the participant at risk because of participation in the study, or may influence the results of the study, or the participant's ability to participate in the study

结局指标

主要结局

Change in serum level of 25 (OH) D

时间窗: 6 weeks

Effect on the vitamin D deficiency level

次要结局

  • Effect on kidney function(6 weeks)
  • Effect on liver enzymes profile(6 weeks)

研究者

发起方
Liaquat University of Medical & Health Sciences
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Amjad Khan

Professor

Liaquat University of Medical & Health Sciences

研究点 (2)

Loading locations...

相似试验